Profil bibliographique

Juan González‐Moreno

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

64Publications signalées

910Citations signalées

1Affiliations récentes

Institutions déclarées

Domaines associés

Amyloidosis: Diagnosis, Treatment, OutcomesParathyroid Disorders and TreatmentsDermatological and Skeletal DisordersIgG4-Related and Inflammatory DiseasesEosinophilic Disorders and Syndromes

Publications récentes

Accès ouvert 2026 articleOpenAlex

Asymptomatic Carrier Neurologic Assessment: A Tool for Early Detection of Symptomatic Transition in Pathogenic TTR Gene Variant Carriers

Isabel Conceição, Juan González‐Moreno, Andoni Echaniz‐Laguna, Kuangnan Xiong et autres

0 citationsEuropean Journal of Neurology

2025 editorialOpenAlex

Revisiting the genetic epidemiology of ATTRv in Spain: the Balearic Islands as a high-prevalence founder focus

Marc Ventayol‐Guirado, Eugenia Cisneros‐Barroso, María Antonia Ribot-Sansó, Juan González‐Moreno et autres

1 citationAmyloid

Accès ouvert 2025 articleOpenAlex

Genetic testing and evidence of a founder mutation in a hotspot for hereditary transthyretin amyloidosis

Marc Ventayol‐Guirado, Eugenia Cisneros‐Barroso, María Antonia Ribot-Sansó, Juan González‐Moreno et autres

4 citationsScientific Reports

Accès ouvert 2025 articleOpenAlex

Economic and healthcare resource utilization for hereditary transthyretin amyloidosis with polyneuropathy in Spain: real-world insights from early-stage patients and mutation carriers

Fernando Martínez Valle, Lucía Galán Dávila, Juan Buades Reinés, Juan González‐Moreno et autres

1 citationExpert Review of Pharmacoeconomics & Outcomes Research

Accès ouvert 2025 articleOpenAlex

Small intestinal bacterial overgrowth in variant transthyretin amyloidosis (A-ATTRv)

Ana Moreno García, Mireia Grimalt Oliver, Juan González‐Moreno, María Antonia Ribot-Sansó et autres

1 citationOrphanet Journal of Rare Diseases

Accès ouvert 2024 articleOpenAlex

Management of Hereditary Transthyretin Amyloidosis (ATTRv) Patients and Asymptomatic Carriers in Spain: The EMPATIa Study

Inés Losada López, Juan González‐Moreno, Juan Buades Reinés, Teresa Sevilla et autres

1 citationJournal of Clinical Medicine

Accès ouvert 2024 articleOpenAlex

A description of variant transthyretin amyloidosis (ATTRv) stage 1 patients and asymptomatic carriers in Spain: the EMPATIa study

Lucía Galán Dávila, Fernando Martinez Valle, Juan Buades Reinés, Juan González‐Moreno et autres

5 citationsOrphanet Journal of Rare Diseases

2024 articleOpenAlex

Recommendations update for the diagnosis and treatment of transthyretin variant amyloidosis (ATTRv)

Juan González‐Moreno, Lucía Galán Dávila, Esther González-López, Isabel Conceição et autres

0 citationsMedicina Clínica (English Edition)

Accès ouvert 2024 articleOpenAlex

Actualización de las recomendaciones para el diagnóstico y tratamiento de la amiloidosis por transtiretina variante (ATTRv)

Juan González‐Moreno, Lucía Galán Dávila, Esther González-López, Isabel Conceição

0 citationsMedicina Clínica

2024 articleOpenAlex

Real life experience of tafamidis for the treatment of Spanish patients with Val30Met transthyretin amyloidosis with polyneuropathy

María Antonia Ribot Sanso, Adrián Rodríguez, Laura Martínez Vicente, Teresa Sevilla et autres

0 citationsMedicina Clínica (English Edition)

2024 articleOpenAlex

Real life experience of tafamidis for the treatment of Spanish patients with Val30Met transthyretin amyloidosis with polyneuropathy

María Antonia Ribot Sanso, Adrián Rodríguez, Laura Martínez Vicente, Teresa Sevilla et autres

2 citationsMedicina Clínica

Accès ouvert 2024 articleOpenAlex

Validating the usefulness of Sudoscan in ATTRv: a single centre experience

Elena Moreno-Moraleda, Juan González‐Moreno, Eugenia Cisneros‐Barroso, María Antonia Ribot-Sansó et autres

5 citationsNeurological Sciences

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.